Scientists track Long-Term impact of blood cancer drug
NCT ID NCT07342712
Summary
This study is observing 40 patients with a bone marrow cancer called myelofibrosis who are already taking the drug gecacitinib from previous trials. Researchers are not giving any new treatment; they are simply collecting yearly bone marrow and blood samples to see how the disease grade and certain gene mutations change over time while patients continue their medication. The goal is to gather long-term safety and effectiveness data on this drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000, China
Conditions
Explore the condition pages connected to this study.